{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=13",
    "query": {
      "intervention": "bispecific antibody",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 362,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T08:10:50.457Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00005813",
      "title": "Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "bispecific antibody MDX447",
          "type": "BIOLOGICAL"
        },
        {
          "name": "lymphokine-activated killer cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-03",
      "completion_date": "2003-01",
      "has_results": false,
      "last_update_posted_date": "2011-10-27",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005813"
    },
    {
      "nct_id": "NCT04806035",
      "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CLL",
        "SLL",
        "Richter's Transformation",
        "Indolent Lymphoma",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Aggressive Lymphoma",
        "DLBCL",
        "Mediastinal Large B-cell Lymphoma",
        "MCL"
      ],
      "interventions": [
        {
          "name": "TG-1801",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ublituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2021-04-28",
      "completion_date": "2024-06-12",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 5,
      "location_summary": "Fayetteville, Arkansas • Hackensack, New Jersey • Chattanooga, Tennessee + 2 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04806035"
    },
    {
      "nct_id": "NCT07648264",
      "title": "Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "IgPro20",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2026-09-15",
      "completion_date": "2029-09-27",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 17,
      "location_summary": "Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07648264"
    },
    {
      "nct_id": "NCT05788484",
      "title": "A Study of CDX-585 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Bladder Urothelial Carcinoma",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Hepatic Cancer",
        "Renal Cell Carcinoma",
        "Cholangiocarcinoma",
        "Pancreatic Cancer",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "CDX-585",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-05-11",
      "completion_date": "2025-05-21",
      "has_results": false,
      "last_update_posted_date": "2025-06-15",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05788484"
    },
    {
      "nct_id": "NCT04695847",
      "title": "M1231 in Participants With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Esophageal Cancer",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "M1231",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-01-13",
      "completion_date": "2023-06-23",
      "has_results": false,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04695847"
    },
    {
      "nct_id": "NCT07563829",
      "title": "NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "NPX372",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NextPoint Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2026-05-01",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Baltimore, Maryland • The Bronx, New York + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07563829"
    },
    {
      "nct_id": "NCT05014412",
      "title": "A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2021-10-07",
      "completion_date": "2025-12-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 35,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fort Collins, Colorado + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05014412"
    },
    {
      "nct_id": "NCT03269136",
      "title": "PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "PF-06863135 monotherapy IV or SC",
          "type": "DRUG"
        },
        {
          "name": "PF-06863135 + dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "PF-06863135 + lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "PF-06863135 + pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2017-11-29",
      "completion_date": "2024-01-19",
      "has_results": true,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 32,
      "location_summary": "Encinitas, California • La Jolla, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03269136"
    },
    {
      "nct_id": "NCT06181786",
      "title": "Study of NAV-240 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "NAV-240",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Navigator Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-11-22",
      "completion_date": "2024-09-04",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06181786"
    },
    {
      "nct_id": "NCT06575686",
      "title": "Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3a Follicular Lymphoma",
        "Refractory Grade 1 Follicular Lymphoma",
        "Refractory Grade 2 Follicular Lymphoma",
        "Refractory Grade 3a Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2025-03-11",
      "completion_date": "2028-07-16",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-18T08:10:50.457Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Irvine, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06575686"
    }
  ]
}